ARTICLE | Clinical News
AtheroGenics completes Phase II
September 26, 2000 7:00 AM UTC
AGIX completed enrollment of 300 patients in its Phase II Canadian Antioxidant Restenosis Trial of AGI-1067, an oral antioxidant small molecule that blocks expression of adhesion molecules, compared t...